This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction. Pharmacoeconomics of Treatment-Resistant Schizophrenia

M. Annette Hanson, MD, Symposium Chair

Published: January 1, 1999

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The National Consensus Conference on the Pharmacoeconomics of Treatment- Resistant Schizophrenia, held in Dallas, Texas, in October 1997, was convened in response to the very serious impact of schizophrenia on our patients, their families,and their communities, as well as the very high expense of treating this illness. The objective of this conference was to bring together health care administrators, physicians, and others in decision-making positions in health care to develop strategies to improve the care given to persons with schizophrenia in hopes of reducing the overall cost of treating this deadly disease.

The meeting focused primarily on treatment-resistant schizophrenia because this is the most serious form of the disease and because the overall management of this illness is a particularly acute problem.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 60

Quick Links: